EA201992284A1 - COMPOSITIONS AND METHODS FOR TREATING SINUCLEINOPATHIES - Google Patents

COMPOSITIONS AND METHODS FOR TREATING SINUCLEINOPATHIES

Info

Publication number
EA201992284A1
EA201992284A1 EA201992284A EA201992284A EA201992284A1 EA 201992284 A1 EA201992284 A1 EA 201992284A1 EA 201992284 A EA201992284 A EA 201992284A EA 201992284 A EA201992284 A EA 201992284A EA 201992284 A1 EA201992284 A1 EA 201992284A1
Authority
EA
Eurasian Patent Office
Prior art keywords
sinucleinopathies
compositions
treating
methods
propylamino
Prior art date
Application number
EA201992284A
Other languages
Russian (ru)
Inventor
Томас Н. Чейс
Кэтлин Э. Клэренс-Смит
Original Assignee
Чейс Терапьютикс Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Чейс Терапьютикс Корпорейшн filed Critical Чейс Терапьютикс Корпорейшн
Priority claimed from PCT/US2018/024344 external-priority patent/WO2018183192A1/en
Publication of EA201992284A1 publication Critical patent/EA201992284A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

В настоящем изобретении описано применение 5HT3-антагониста в комбинации с 6-пропиламино-4,5,6,7-тетрагидро-1,3-бензотиазол-2-амином для снижения побочных эффектов и облегчения нейропротективного лечения пациента, страдающего синуклеинопатическим расстройством, для обеспечения терапевтически эффективной суточной дозы 6-пропиламино-4,5,6,7-тетрагидро-1,3-бензотиазол-2-амина без ограничивающих дозу нежелательных явлений, вызываемых прамипексолом при применении по отдельности.The present invention describes the use of a 5HT3 antagonist in combination with 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine to reduce side effects and facilitate the neuroprotective treatment of a patient suffering from synucleinopathic disorder to provide a therapeutically effective daily dose of 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine without dose-limiting adverse events caused by pramipexole when used separately.

EA201992284A 2017-07-03 2018-03-26 COMPOSITIONS AND METHODS FOR TREATING SINUCLEINOPATHIES EA201992284A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762528228P 2017-07-03 2017-07-03
PCT/US2018/024344 WO2018183192A1 (en) 2017-03-27 2018-03-26 Compositions and methods for treating synucleinopathies

Publications (1)

Publication Number Publication Date
EA201992284A1 true EA201992284A1 (en) 2020-03-12

Family

ID=69942840

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992284A EA201992284A1 (en) 2017-07-03 2018-03-26 COMPOSITIONS AND METHODS FOR TREATING SINUCLEINOPATHIES

Country Status (1)

Country Link
EA (1) EA201992284A1 (en)

Similar Documents

Publication Publication Date Title
EA201790088A1 (en) SYK INHIBITORS
PH12020551425A1 (en) Rimegepant for cgrp related disorders
PH12018501903A1 (en) Methods of treating depression using orexin-2 receptor antagonists
EA202090510A1 (en) METHOD FOR TREATMENT OF LATERAL AMYOTROPHIC SCLEROSIS BY PRIDOPIDIN
EA201990951A1 (en) COMBINATIONS CONTAINING SSAO / VAP-1 INHIBITOR AND SGLT2 INHIBITOR, AND THEIR APPLICATION
MX2018003893A (en) Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough.
EA201790305A1 (en) COMBINED THERAPY OF AlZHEIMER'S DISEASE USING THE COMBINATION OF MONOCLONAL ANTIBODIES TO N3pGlu ABETA AND BACE INHIBITOR
EA201990424A1 (en) SPIRALACTAM MODULERS OF NMDA RECEPTOR AND THEIR APPLICATION
PH12016502352A1 (en) Pharmaceutical composition
EA201990428A1 (en) SPIRALACTAM MODULERS OF NMDA RECEPTOR AND THEIR APPLICATION
PH12016502353A1 (en) Pharmaceutical composition
BR112022002609A2 (en) METHODS OF TREATMENT OF GASTROINTESTINAL STROMAL TUMORS
MY195038A (en) A Modified Release Composition of Orlistat and Acarbose for the Treatment of Obesity and Related Metabolic Disorders
EA201991387A1 (en) TRICYCLIC JONES - PYRIMIDINE DERIVATIVES FOR INHIBITING ROR-γ AND OTHER APPLICATIONS
EA201991650A1 (en) METHODS FOR TREATING NEUROLOGICAL DISORDERS
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
MX2021002322A (en) Novel methods.
EA201991175A1 (en) THE USE OF INTERFERON-LAMBDA IN MEDICINE FOR THE TREATMENT OF FIBROSIS
MX2023000187A (en) Dosing of vibegron for treatment of overactive bladder.
EA202092225A1 (en) CONNECTIONS AND THEIR APPLICATION
EA201792264A1 (en) METHODS OF TREATING INFLAMMATORY DISEASES
EA201691656A2 (en) THERAPEUTIC WAYS WITH THE USE OF NORIBOGOGINE AND RELATED COMPOUNDS
EA202091112A1 (en) SOCRYSTALS, PHARMACEUTICAL COMPOSITIONS BASED ON THEIR BASED AND METHODS OF TREATMENT FOR THEIR APPLICATION
EA201992284A1 (en) COMPOSITIONS AND METHODS FOR TREATING SINUCLEINOPATHIES
EA201990559A1 (en) COMBINED THERAPY